Barclays
VERV

Barclays’s Verve Therapeutics VERV Stock Holding History

Barclays’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-301,599
Closed -$3.39M – 5746
2025
Q2 		$3.39M Buy
301,599
+114,631
+61% +$653K ﹤0.01% 2425
2025
Q1 		$854K Sell
186,968
-33,763
-15% -$226K ﹤0.01% 3200
2024
Q4 		$1.24M Sell
220,731
-2,188
-1% -$12.3K ﹤0.01% 3227
2024
Q3 		$1.08M Buy
222,919
+129,944
+140% +$755K ﹤0.01% 3307
2024
Q2 		$454K Buy
92,975
+13,318
+17% +$83.7K ﹤0.01% 3096
2024
Q1 		$1.06M Sell
79,657
-114,971
-59% -$1.52M ﹤0.01% 3076
2023
Q4 		$2.71M Buy
194,628
+50,410
+35% +$625K ﹤0.01% 2661
2023
Q3 		$1.91M Buy
144,218
+22,898
+19% +$369K ﹤0.01% 1933
2023
Q2 		$2.27M Buy
121,320
+12,474
+11% +$208K ﹤0.01% 1811
2023
Q1 		$1.57M Sell
108,846
-93,543
-46% -$1.83M ﹤0.01% 2379
2022
Q4 		$3.92M Buy
202,389
+88,718
+78% +$2.35M ﹤0.01% 1792
2022
Q3 		$3.9M Buy
113,671
+108,815
+2,241% +$3.47M ﹤0.01% 1316
2022
Q2 		$74K Sell
4,856
-20,139
-81% -$312K ﹤0.01% 3895
2022
Q1 		$571K Buy
+24,995
New +$714K ﹤0.01% 2817

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Barclays's VERV Position: Q3 2025 in Review

Barclays sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 301,599 shares — an estimated $3.39M sold.

Barclays first reported a position in VERV in Q1 2022 and held it in 14 quarters. The position peaked at $3.92M in Q4 2022. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Barclays reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Barclays sold 301,599 Verve Therapeutics shares in Q3 2025, an estimated $3.39M.
  • Barclays first reported a position in Verve Therapeutics in Q1 2022 and held it in 14 quarters.
  • Barclays's Verve Therapeutics position peaked at $3.92M in Q4 2022.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.